Dornase alfa Discount Contract
Original notice title
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-12 - Dornase alfa
Opportunity Score
Why this score?
Opportunity
70 / 100
Complexity
30 / 100
Risk factors
Failure to provide correct self-declaration or meet authorization requirements leads to exclusion.
Initial deadline for January 2025 inclusion is very short (2 Dec 2024).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Conclusion of discount contracts for Dornase alfa under §130a Abs. 8 SGB V
- Open-House procedure with standardized terms and individual negotiation
Show full summary
Open-House procedure for discount contracts (Rabattverträge) for the active substance Dornase alfa. Contracting parties: Techniker Krankenkasse and HEK. Contract duration up to 24 months (01.01.2025 to 31.12.2026). Open to all eligible pharmaceutical entrepreneurs. No exclusivity, no negotiation of individual terms.
Risks
Failure to provide correct self-declaration or meet authorization requirements leads to exclusion.
Initial deadline for January 2025 inclusion is very short (2 Dec 2024).
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG
- Must hold a valid marketing authorization for Dornase alfa in Germany
- Must be located in EU/EEA
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Dornase alfa Discount Contract
Conclusion of discount contracts for medicinal products with active substance Dornase alfa under the Open-House procedure.
Location
Duration
Category
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Dornase alfa im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original lot title
Open-House-Biologika-Rabattverträge 2024-12 - Dornase alfa
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Dornase alfa im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 17 Nov 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 702179-2024
Documents (1)
Similar tenders
Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)
Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów
France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord
Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)
Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ
Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).
Opportunity Score
Why this score?
Opportunity
70 / 100
Complexity
30 / 100
Risk factors
Failure to provide correct self-declaration or meet authorization requirements leads to exclusion.
Initial deadline for January 2025 inclusion is very short (2 Dec 2024).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications